Literature DB >> 24145905

Clinicopathologic review of epithelial tumors of the lacrimal gland.

Bhavna Chawla1, Seema Kashyap, Seema Sen, Mandeep S Bajaj, Neelam Pushker, Kamlesh Gupta, Mahesh Chandra, Supriyo Ghose.   

Abstract

OBJECTIVE: To study the clinicopathologic features of epithelial tumors of the lacrimal gland diagnosed at a tertiary care center in India during a 10-year period.
METHODS: Medical records of cases with histopathologically proven epithelial tumors of the lacrimal gland were reviewed for demographic details and clinical features at the time of presentation. For histopathologic findings, slides with hemotoxylin and eosin-stained sections of the tumors were reviewed. Special stains, including histochemical and immunohistochemical stains, and additional sections were studied, whenever needed.
RESULTS: Of 66 cases with epithelial tumors of the lacrimal gland identified during the study period, 50 (76%) cases were benign and 16 (24%) cases were malignant tumors. Histopathologic examination was consistent with the diagnosis of pleomorphic adenoma (PA) in all 50 cases of benign tumors. The mean age at diagnosis in PA cases was 37.7 years. Microscopic examination of PA tumors showed cystic degeneration in 18 (36%) cases, squamous metaplasia in 16 (32%) cases, calcification in 6 (12%) cases, and ossification in 1 (2%) case. Among malignant tumors, adenoid cystic carcinoma (ACC) was the most common tumor (n = 12, 18%), with an average age at diagnosis of 32.4 years. Microscopic examination of ACC revealed that most cases were grade I tumors. Solid areas were noted in 4 (33.3%) cases and perineural invasion was identified in 2 (16.7%) cases. Other malignant tumors included 1 case each of carcinoma ex-PA (1.5%), lacrimal duct carcinoma (1.5%), mucoepidermoid carcinoma (1.5%), and basal cell adenocarcinoma (1.5%).
CONCLUSIONS: As far as the authors are aware, this is the largest series on clinicopathologic features of epithelial tumors of the lacrimal gland from South Asia. The incidence of PA was significantly higher in this study than reported in the Caucasian population. Among malignant tumors, ACCs were the most common, although rare tumors were also identified.

Entities:  

Mesh:

Year:  2013        PMID: 24145905     DOI: 10.1097/IOP.0b013e31829f3a0c

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  6 in total

1.  GCDFP-15, AR, and Her-2 as biomarkers for primary ductal adenocarcinoma of the lacrimal gland: a Chinese case and literature review.

Authors:  Miao-Miao Zhu; Hong-Guang Cui; Xiao-Dong Teng
Journal:  Onco Targets Ther       Date:  2015-05-11       Impact factor: 4.147

2.  Outcomes in patients with lacrimal gland carcinoma treated with definitive radiotherapy or eye-sparing surgery followed by adjuvant radiotherapy.

Authors:  Yun-Hsuan Lin; Shih-Ming Huang; Wing-Keen Yap; Ju-Wen Yang; Ling Yeung; Din-Li Tsan; Joseph Tung-Chieh Chang; Lung-Chien Chen
Journal:  Radiat Oncol       Date:  2020-06-22       Impact factor: 3.481

3.  Fibroblast growth factor receptor 1 (FGFR1) as a therapeutic target in adenoid cystic carcinoma of the lacrimal gland.

Authors:  Ravi Doddapaneni; Wensi Tao; Andrea Naranjo; Neda Nikpoor; David T Tse; Daniel Pelaez
Journal:  Oncotarget       Date:  2019-01-11

4.  Bevacizumab is an Efficient Therapeutic Approach with Low Side Effects in Patient-Derived Xenografts of Adenoid Cystic Carcinoma of the Lacrimal Gland.

Authors:  Jingxue Zhang; Xuejing Yan; Rui Liu; Shen Wu; Qian Liu; Jing Li; Jianmin Ma
Journal:  Cancer Manag Res       Date:  2022-03-06       Impact factor: 3.989

5.  Epithelial Lacrimal Gland Tumours in Nigeria: Clinicopathological Features and Treatment.

Authors:  Oluyemi Fasina; Adewunmi Oluseye Adeoye; Olanipekun Olalekan Aremu
Journal:  J West Afr Coll Surg       Date:  2022-03-26

6.  Current Trends in the Management of Epithelial Lacrimal Gland Tumors: A Retrospective National Cancer Database Analysis.

Authors:  Prashanth Ashok Kumar; Dongliang Wang; Danning Huang; Shweta Paulraj; Abirami Sivapiragasam
Journal:  Cureus       Date:  2022-07-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.